AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 19 - (NewsRx.com & NewsRx.net) -- AlphaVax, Inc., announced that it has received notice of a new 5-year, $16.8 million contract from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services.
The award supports the development of a vaccine for HIV using the company's proprietary vaccine technology under a special program from the Division of AIDS in the NIAID called the HIV Vaccine Design & Development Teams. This program is aimed at technologies that show promise beyond the early research phase, and provide funding for preclinical development, production of vaccine material for clinical trials, and clinical studies.
In July of this year, the company announced that it had initiated its first clinical trial under the auspices of the HIV Vaccine Trial Network (HVTN), a partnership of investigators, clinical trial sites, and community representatives working with industry and governments in the global search for a preventive HIV vaccine, and which is funded by NIAID. This latest award significantly extends the support that AlphaVax has received for its HIV vaccine program from the NIH, including $5.5 million that was awarded in 2002 under a 2-year cooperative agreement.
The AlphaVax vaccine technology is based on its proprietary ArV system. This system is of ...
Source: HighBeam Research, New $16.8M NIH award supports development of vaccine.